Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Standardization of red flags for referral to rheumatologists and ophthalmologists in patients with rheumatic diseases and ocular involvement: a consensus statement.

Olivieri I, Accorinti M, Abicca I, Bisceglia P, Cimino L, Latanza L, Leccese P, Lubrano E, Marchesoni A, Miserocchi E, Neri P, Salvarani C, Scarpa R, D'Angelo S; CORE Study Group.

Rheumatol Int. 2018 Jun 30. doi: 10.1007/s00296-018-4094-1. [Epub ahead of print]

PMID:
29961101
2.

Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study.

Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, Sardu C, Scarpa R, Marchesoni A, Taylor WJ, Salvarani C, Kalden J, Lubrano E, Carneiro S, Piga M, Floris A, Desiati F, Flynn JA, D'Angelo S, van Kuijk AWR, Catanoso MG, Caso F, Contu P, Ujfalussy I, Helliwell PS, Mease PJ; for the GRAPPA 3PPsA Study Group.

J Rheumatol. 2018 Jun 15. pii: jrheum.171183. doi: 10.3899/jrheum.171183. [Epub ahead of print]

PMID:
29907666
3.

The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry.

Favalli EG, Becciolini A, Biggioggero M, Bertoldi I, Crotti C, Raimondo MG, Marchesoni A.

Drug Des Devel Ther. 2018 May 24;12:1421-1429. doi: 10.2147/DDDT.S162286. eCollection 2018.

4.

Oligoarticular Psoriatic Arthritis: Addressing Clinical Challenges in an Intriguing Phenotype.

Marchesoni A.

Rheumatol Ther. 2018 Jun 1. doi: 10.1007/s40744-018-0115-5. [Epub ahead of print]

5.

Life-threatening reversible bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximab.

Marchesoni A, Arreghini M, Panni B, Battafarano N, Uziel L.

Rheumatology (Oxford). 2018 Jun 1;57(6):1128. doi: 10.1093/rheumatology/key094. No abstract available.

PMID:
29608766
6.

Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease.

Rizzello F, Olivieri I, Armuzzi A, Ayala F, Bettoli V, Bianchi L, Cimino L, Costanzo A, Cristaudo A, D'Angelo S, Daperno M, Fostini AC, Galeazzi M, Gilio M, Gionchetti P, Gisondi P, Lubrano E, Marchesoni A, Offidani A, Orlando A, Pugliese D, Salvarani C, Scarpa R, Vecchi M, Girolomoni G.

Adv Ther. 2018 Apr;35(4):545-562. doi: 10.1007/s12325-018-0672-6. Epub 2018 Mar 7.

7.

The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis.

Lubrano E, Perrotta FM, Manara M, D'Angelo S, Addimanda O, Ramonda R, Punzi L, Olivieri I, Salvarani C, Marchesoni A.

J Rheumatol. 2018 Feb;45(2):195-201. doi: 10.3899/jrheum.170666.

PMID:
29419448
8.

Prevalence and incidence of psoriatic arthritis: A systematic review and meta-analysis.

Scotti L, Franchi M, Marchesoni A, Corrao G.

Semin Arthritis Rheum. 2018 Aug;48(1):28-34. doi: 10.1016/j.semarthrit.2018.01.003. Epub 2018 Jan 6.

PMID:
29398124
9.

Consensus on the management of patients with psoriatic arthritis in a dermatology setting.

Gisondi P, Altomare G, Ayala F, Conti A, Dapavo P, De Simone C, Foti C, Idolazzi L, Lubrano E, Malara G, Marchesoni A, Olivieri I, Parodi A, Peris K, Piaserico S, Salvarani C, Scarpa R, Girolomoni G.

J Eur Acad Dermatol Venereol. 2018 Apr;32(4):515-528. doi: 10.1111/jdv.14741. Epub 2018 Jan 11.

PMID:
29220551
10.

Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology.

Marchesoni A, Olivieri I, Salvarani C, Pipitone N, D'Angelo S, Mathieu A, Cauli A, Punzi L, Ramonda R, Scarpa R, Maccarone M, Lubrano E.

Clin Exp Rheumatol. 2017 Nov-Dec;35(6):991-1010. Epub 2017 Nov 28.

PMID:
29185959
11.

The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis.

Lubrano E, Perrotta FM, Manara M, D'Angelo S, Addimanda O, Ramonda R, Punzi L, Olivieri I, Salvarani C, Marchesoni A.

J Rheumatol. 2017 Nov 15. pii: jrheum.17666. doi: 10.3899/jrheum.17666. [Epub ahead of print]

PMID:
29142035
12.

Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs.

Atzeni F, Carletto A, Foti R, Sebastiani M, Panetta V, Salaffi F, Bonitta G, Iannone F, Gremese E, Govoni M, Marchesoni A, Favalli EG, Gorla R, Ramonda R, Sarzi-Puttini P, Ferraccioli G, Lapadula G; GISEA group.

Joint Bone Spine. 2018 Jul;85(4):455-459. doi: 10.1016/j.jbspin.2017.08.003. Epub 2017 Sep 8.

PMID:
28893679
13.

Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts.

Armuzzi A, Felice C, Lubrano E, Cantini F, Castiglione F, Gionchetti P, Orlando A, Salvarani C, Scarpa R, Marchesoni A, Vecchi M, Olivieri I; Italian SpA-IBD Expert Panel Group.

Dig Liver Dis. 2017 Dec;49(12):1298-1305. doi: 10.1016/j.dld.2017.06.004. Epub 2017 Jun 23. Review.

PMID:
28822731
14.

Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.

Favalli EG, Pontikaki I, Becciolini A, Biggioggero M, Ughi N, Romano M, Crotti C, Gattinara M, Gerloni V, Marchesoni A, Meroni PL.

Clin Rheumatol. 2017 Aug;36(8):1747-1755. doi: 10.1007/s10067-017-3712-8. Epub 2017 Jun 8.

PMID:
28597133
15.

The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia.

Marchesoni A, De Marco G, Merashli M, McKenna F, Tinazzi I, Marzo-Ortega H, McGonagle DG.

Rheumatology (Oxford). 2018 Jan 1;57(1):32-40. doi: 10.1093/rheumatology/kex079. Review.

16.

Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry.

Monti S, Klersy C, Gorla R, Sarzi-Puttini P, Atzeni F, Pellerito R, Fusaro E, Paolazzi G, Rocchetta PA, Favalli EG, Marchesoni A, Caporali R.

Clin Rheumatol. 2017 Apr;36(4):753-761. doi: 10.1007/s10067-016-3528-y. Epub 2017 Jan 5.

PMID:
28058538
17.

Evidence-based algorithm for diagnosis and assessment in psoriatic arthritis: results by Italian DElphi in psoriatic Arthritis (IDEA).

Lapadula G, Marchesoni A, Salaffi F, Ramonda R, Salvarani C, Punzi L, Costa L, Caso F, Simone D, Baiocchi G, Scioscia C, Di Carlo M, Scarpa R, Ferraccioli G.

Reumatismo. 2016 Dec 16;68(3):126-136. doi: 10.4081/reumatismo.2016.913.

18.

Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis.

Favalli EG, Selmi C, Becciolini A, Biggioggero M, Ariani A, Santilli D, Fusaro E, Parisi S, Massarotti M, Marchesoni A, Meroni PL.

Arthritis Care Res (Hoboken). 2017 Jun;69(6):867-874. doi: 10.1002/acr.23090.

19.

A national survey on the management of psoriatic arthritis using the Delphi method.

Lubrano E, Cantini F, Mathieu A, Olivieri I, Salvarani C, Scarpa R, Marchesoni A.

Clin Exp Rheumatol. 2017 Mar-Apr;35(2):214-220. Epub 2016 Aug 31.

PMID:
27607572
20.

Impact of training on concordance among rheumatologists and dermatologists in the assessment of patients with psoriasis and psoriatic arthritis.

Salvarani C, Girolomoni G, Di Lernia V, Gisondi P, Tripepi G, Egan CG, Marchesoni A; DREAM study group.

Semin Arthritis Rheum. 2016 Dec;46(3):305-311. doi: 10.1016/j.semarthrit.2016.06.004. Epub 2016 Jun 21.

PMID:
27470190
21.

Current approach to the management of psoriatic arthritis according to a sample of Italian rheumatologists.

Marchesoni A, Lubrano E, Manara M, Ramonda R, Salvarani C, Olivieri I.

Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1051-1058. Epub 2016 Jul 26.

PMID:
27462870
22.

Predictors of Loss of Remission and Disease Flares in Patients with Axial Spondyloarthritis Receiving Antitumor Necrosis Factor Treatment: A Retrospective Study.

Lubrano E, Massimo Perrotta F, Manara M, D'Angelo S, Addimanda O, Ramonda R, Punzi L, Olivieri I, Salvarani C, Marchesoni A.

J Rheumatol. 2016 Aug;43(8):1541-6. doi: 10.3899/jrheum.160363. Epub 2016 Jun 1. Erratum in: J Rheumatol. 2016 Sep;43(9):1772.

PMID:
27252428
23.

Early clinical response predicts low disease activity at one year in rheumatoid arthritis patients on treatment with certolizumab in real-life settings. An appraisal of the Italian registry GISEA.

Iannone F, Carlino G, Marchesoni A, Sarzi-Puttini P, Gorla R, Lapadula G; GISEA (Gruppo Italiano di Studio sulle Early Arthritides).

Joint Bone Spine. 2016 Dec;83(6):721-725. doi: 10.1016/j.jbspin.2015.12.004. Epub 2016 Apr 23.

PMID:
27118021
24.

Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey.

Ramonda R, Marchesoni A, Carletto A, Bianchi G, Cutolo M, Ferraccioli G, Fusaro E, De Vita S, Galeazzi M, Gerli R, Matucci-Cerinic M, Minisola G, Montecucco C, Pellerito R, Salaffi F, Paolazzi G, Sarzi-Puttini P, Scarpa R, Bagnato G, Triolo G, Valesini G, Punzi L, Olivieri I; ATLANTIS study group.

Arthritis Res Ther. 2016 Apr 1;18:78. doi: 10.1186/s13075-016-0977-2.

25.

Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.

Varisco V, Viganò M, Batticciotto A, Lampertico P, Marchesoni A, Gibertini P, Pellerito R, Rovera G, Caporali R, Todoerti M, Covelli M, Notarnicola A, Atzeni F, Sarzi-Puttini P.

J Rheumatol. 2016 May;43(5):869-74. doi: 10.3899/jrheum.151105. Epub 2016 Feb 15.

PMID:
26879359
26.

Efficacy of cyclosporine A as monotherapy in patients with psoriatic arthritis: a subgroup analysis of the SYNERGY Study.

Colombo D, Chimenti S, Grossi PA, Marchesoni A, Foti R, Calzavara-Pinton P, Zagni E, Ori A, Bellia G; SYNERGY Study Group.

G Ital Dermatol Venereol. 2017 Jun;152(3):297-301. doi: 10.23736/S0392-0488.16.05301-3. Epub 2016 Feb 2.

PMID:
26837484
27.
28.

Atypical Bone Sclerosis.

Ricci M, Bettazzi LG, Varenna M, Marchesoni A.

Arthritis Rheumatol. 2016 Apr;68(4):816. doi: 10.1002/art.39556. No abstract available.

29.

Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.

Perrotta FM, Marchesoni A, Lubrano E.

J Rheumatol. 2016 Feb;43(2):350-5. doi: 10.3899/jrheum.150805. Epub 2015 Dec 15.

PMID:
26669925
30.

Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.

Favalli EG, Pregnolato F, Biggioggero M, Becciolini A, Penatti AE, Marchesoni A, Meroni PL.

Arthritis Care Res (Hoboken). 2016 Apr;68(4):432-9. doi: 10.1002/acr.22788.

31.

New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.

Cauli A, Piga M, Lubrano E, Marchesoni A, Floris A, Mathieu A.

J Rheumatol Suppl. 2015 Nov;93:70-2. doi: 10.3899/jrheum.150641. Review.

PMID:
26523062
32.

Psoriatic Disease: Update on Traditional Disease-modifying Antirheumatic Drugs.

Marchesoni A, Lubrano E, Cauli A, Ricci M, Manara M.

J Rheumatol Suppl. 2015 Nov;93:61-4. doi: 10.3899/jrheum.150639. Review.

PMID:
26523060
33.

The Definition and Measurement of Axial Psoriatic Arthritis.

Lubrano E, Parsons WJ, Marchesoni A, Olivieri I, D'Angelo S, Cauli A, Caso F, Costa L, Scarpa R, Brunese L.

J Rheumatol Suppl. 2015 Nov;93:40-2. doi: 10.3899/jrheum.150634. Review.

PMID:
26523055
34.

Patient's Global Assessment as an Outcome Measure for Psoriatic Arthritis in Clinical Practice: A Surrogate for Measuring Low Disease Activity?

Lubrano E, Perrotta FM, Parsons WJ, Marchesoni A.

J Rheumatol. 2015 Dec;42(12):2332-8. doi: 10.3899/jrheum.150595. Epub 2015 Nov 1.

PMID:
26523033
35.

Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.

Cantini F, Lubrano E, Marchesoni A, Mathieu A, Olivieri I, Salvarani C, Scarpa R, Spadaro A.

Int J Rheum Dis. 2016 Aug;19(8):799-805. doi: 10.1111/1756-185X.12708. Epub 2015 Jul 14.

PMID:
26172207
36.

Five-year survival on infliximab in rheumatoid arthritis patients: analysis from an Italian registry (GISEA) by different calendar years.

Iannone F, Salaffi F, Marchesoni A, Gorla R, Atzeni F, Govoni M, Gremese E, Lapadula G, On Behalf Of Gisea Gruppo Italiano di Studio Sulle Early Arthritides A.

Clin Exp Rheumatol. 2015 Jul-Aug;33(4):524-30. Epub 2015 Jun 19.

PMID:
26087761
37.

Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies.

Favalli EG, Biggioggero M, Marchesoni A, Meroni PL.

Rheumatology (Oxford). 2015 Jul;54(7):1337. doi: 10.1093/rheumatology/kev209. Epub 2015 Jun 5. No abstract available.

PMID:
26047991
38.

Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study.

Lubrano E, Perrotta FM, Marchesoni A, D'Angelo S, Ramonda R, Addimanda O, Olivieri I, Punzi L, Salvarani C.

J Rheumatol. 2015 Feb;42(2):258-63. doi: 10.3899/jrheum.140811. Epub 2014 Dec 15.

PMID:
25512483
39.

The EPIPSOFIRE project: a preliminary report.

De Marco G, Cattaneo A, Carrera CG, Gibertini P, Battafarano N, Marchesoni A.

Drug Dev Res. 2014 Nov;75 Suppl 1:S85-7. doi: 10.1002/ddr.21205.

PMID:
25381988
40.

Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.

Perrotta FM, Addimanda O, Ramonda R, D'Angelo S, Lubrano E, Marchesoni A, Olivieri I, Punzi L, Salvarani C, Spadaro A.

Reumatismo. 2014 Nov 6;66(3):208-14. doi: 10.4081/reumatismo.2014.756.

41.

Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registry.

Favalli EG, Becciolini A, Biggioggero M, Marchesoni A, Meroni PL.

Ann Rheum Dis. 2015 Jan;74(1):e5. doi: 10.1136/annrheumdis-2014-206651. Epub 2014 Oct 10. No abstract available.

PMID:
25304319
42.

Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: long-term real-life data from the Lorhen Registry.

Filippini M, Bazzani C, Atzeni F, Sarzi Puttini P, Marchesoni A, Favalli EG, Caporali R, Cavagna L, Gorla R.

Biomed Res Int. 2014;2014:416892. doi: 10.1155/2014/416892. Epub 2014 Jul 6.

43.

Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register.

Sebastiani M, Anelli MG, Atzeni F, Bazzani C, Farina I, Fedele AL, Favalli EG, Fineschi I, Cino N, Dal Forno I, Gasparini S, Cassarà E, Giardina R, Bruschi E, Addimanda O, Cassone G, Lopriore S, Sarzi-Puttini P, Filippini M, Pignatti F, Gremese E, Biggioggero M, Manganelli S, Amato G, Caimmi C, Salaffi F, Iannone F, Ferri C, Sandri G, Lapadula G, Gorla R, Govoni M, Ferraccioli G, Marchesoni A, Galeazzi M, Foti R, Carletto A, Cantini F, Triolo G, Epis OM, Salvarani C; Italian Study Group on Early Arthritides (GISEA).

Joint Bone Spine. 2014 Dec;81(6):508-12. doi: 10.1016/j.jbspin.2014.06.011. Epub 2014 Jul 28.

PMID:
25082646
44.

The adherence to ASAS classification criteria and to ASAS recommendations for the use of anti-TNH-alpha agents in axial spondyloarthritis.

Spadaro A, Lubrano E, Marchesoni A, Cauli A, Cantini F, Carotti M, D'Angelo S, Grassi W, Lapadula G, Macchioni P, Mathieu A, Punzi L, Ramonda R, Salaffi F, Salvarani C, Scarpa R, Olivieri I.

Clin Exp Rheumatol. 2014 Jul-Aug;32(4):465-70. Epub 2014 May 21.

PMID:
24850468
45.

Prevalence of past and reactivated viral infections and efficacy of cyclosporine A as monotherapy or in combination in patients with psoriatic arthritis--synergy study: a longitudinal observational study.

Colombo D, Chimenti S, Grossi P, Marchesoni A, Di Nuzzo S, Griseta V, Gargiulo A, Parodi A, Simoni L, Bellia G.

Biomed Res Int. 2014;2014:941767. doi: 10.1155/2014/941767. Epub 2014 Apr 3.

46.

Adalimumab in the treatment of immune-mediated diseases.

Lapadula G, Marchesoni A, Armuzzi A, Blandizzi C, Caporali R, Chimenti S, Cimaz R, Cimino L, Gionchetti P, Girolomoni G, Lionetti P, Marcellusi A, Mennini FS, Salvarani C.

Int J Immunopathol Pharmacol. 2014 Jan-Mar;27(1 Suppl):33-48. Review.

PMID:
24774505
47.

anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.

Armuzzi A, Lionetti P, Blandizzi C, Caporali R, Chimenti S, Cimino L, Gionchetti P, Girolomoni G, Lapadula G, Marchesoni A, Marcellusi A, Mennini FS, Salvarani C, Cimaz R.

Int J Immunopathol Pharmacol. 2014 Jan-Mar;27(1 Suppl):11-32. Review.

PMID:
24774504
48.

The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases.

Blandizzi C, Gionchetti P, Armuzzi A, Caporali R, Chimenti S, Cimaz R, Cimino L, Lapadula G, Lionetti P, Marchesoni A, Marcellusi A, Mennini FS, Salvarani C, Girolomoni G.

Int J Immunopathol Pharmacol. 2014 Jan-Mar;27(1 Suppl):1-10. Review.

PMID:
24774503
49.

Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies.

Favalli EG, Biggioggero M, Marchesoni A, Meroni PL.

Rheumatology (Oxford). 2014 Sep;53(9):1664-8. doi: 10.1093/rheumatology/keu158. Epub 2014 Apr 12. Erratum in: Rheumatology (Oxford). 2015 Jul;54(7):1337.

PMID:
24729445
50.

High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register.

Iannone F, Gremese E, Gallo G, Sarzi-Puttini P, Botsios C, Trotta F, Gasperini S, Galeazzi M, Adami S, Cantini F, Sebastiani M, Gorla R, Marchesoni A, Giardina A, Foti R, Mele A, Bruschi E, Bagnato G, Erre GL, Lapadula G; GISEA (Gruppo Italiano Studio Early Arthritis).

Clin Rheumatol. 2014 Jan;33(1):31-7. doi: 10.1007/s10067-013-2348-6. Epub 2013 Aug 18.

PMID:
23954923

Supplemental Content

Loading ...
Support Center